title: Molecular analysis of beta-thalassemia and sickle cell anemia in Antalya.
abstract: We have studied 918 chromosomes for mutations leading to beta-thalassemia and sickle cell anemia, which are the two most frequently found monogenic disorders in Antalya, Turkey. Three hundred and seventy-seven postnatal and 82 prenatal cases were studied between 2000 and May 2003 in our center using reverse dot blot hybridization (RDBH) with 22 probes specific for Mediterranean populations. In this study, IVSI-110 (G-->A) appeared to be the most common mutation with an occurrence rate of 44.4% among the 16 different mutations found to be associated with beta-thalassemia. Heterozygosity for IVSI-110 was the most prevalent combination, whereas 34 of our 377 postnatal cases showed homozygosity for this mutation, a genotype leading to beta-thalassemia major. The total percentage of postnatal patients clinically diagnosed as beta-thalassemia major was 18.6%, whereas 5% of the cases were diagnosed clinically as beta-thalassemia intermedia. One new Hb variant, Hb Antalya, and one new mutation, Cod 3 (+T) were found. HbS accounted for 10.3% of all mutations; homozygosity was found in 1.9% of all cases. Of the 82 cases analysed prenatally for beta-globin gene mutations and by cytogenetic techniques for possible chromosomal abnormalities, 21 fetuses were found to be affected with beta-globin gene mutations. One of these fetuses was also found to have a 45,X karyotype, and 1 had a 46,XY/47,XY,+22 karyotype. Quite a high rate of consanguineous marriages in Antalya (35.17%) renders mutation screening, genetic counseling, and educational programs held by our Thalassemia Unit essential. This study was the first to be performed specifically in our region where hemoglobinopathies are most frequent as a consequence of migrations of racially and culturally distinct groups to the area in the distant past.
authors.affiliation: Department of Medical Biology and Genetics, Akdeniz University School of Medicine, Antalya, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Keser
authors.forename: A D
authors.initials: AD
authors.lastname: Sanlioglu
authors.forename: E
authors.initials: E
authors.lastname: Manguoglu
authors.forename: O
authors.initials: O
authors.lastname: Guzeloglu Kayisli
authors.forename: N
authors.initials: N
authors.lastname: Nal
authors.forename: F
authors.initials: F
authors.lastname: Sargin
authors.forename: A
authors.initials: A
authors.lastname: Yesilipek
authors.forename: M
authors.initials: M
authors.lastname: Simsek
authors.forename: I
authors.initials: I
authors.lastname: Mendilcioglu
authors.forename: D
authors.initials: D
authors.lastname: Canatan
authors.forename: G
authors.initials: G
authors.lastname: Luleci
mesh_terms: D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000453:epidemiology / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D004252:DNA Mutational Analysis; D005333:Fetus; D005787:Gene Frequency; D005838:Genotype; D006451:Hemoglobin, Sickle / Q000235:genetics; D006455:Hemoglobins, Abnormal / Q000235:genetics*; D006801:Humans; D007223:Infant; D017720:Molecular Epidemiology; D011296:Prenatal Diagnosis; D014421:Turkey / Q000453:epidemiology; D017086:beta-Thalassemia / Q000453:epidemiology / Q000235:genetics*
chemical_list: D006451:Hemoglobin, Sickle; D006455:Hemoglobins, Abnormal